Per GEN, Vivalis reported the achievement of a significant milestone in its collaboration with GSK Biologicals on the production of flu vaccines in the Vivalis EB66 cell line. The milestone recognizes the characterization of the cell line to meet relevant regulatory guidelines.
SAFC has worked closely with Vivalis to produce serum-free and chemically-defined (EBx) media for the growth of the EB66 cell line in the production of a variety of viruses, including flu. We are pleased to see the EB66 cell line continues to make inroads for cell-based vaccine production in replacement of the older egg-based methods.
Posted by Bruce Lehr April 8th 2010